Breast Cancer Clinical Trial
— PALMIRAOfficial title:
International,Multicenter,Randomized,Open-label, Phase II to Evaluate the Efficacy and Safety of Continuation of Palbociclib+2nd Line Endocrine Therapy in HR+/HER2- ABC Patients Who Had Clinical Benefit During 1st Line Palbociclib.
Verified date | September 2023 |
Source | MedSIR |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Hormone Receptor (HR)-positive/Human Epidermal Growth Factor Receptor 2 (HER2)-negative advanced breast cancer (ABC)
Status | Completed |
Enrollment | 198 |
Est. completion date | November 30, 2022 |
Est. primary completion date | November 30, 2022 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Female patients over 18 years of age. 2. Pre-menopausal women provided they are being treated with a LHRH analogue for at least 28 days (if shorter, post-menopausal levels of serum estradiol/Follicle-stimulating hormone (FSH) must be confirmed analytically) prior to study entry or post- menopausal women as defined by any of the following criteria: 1. Age =60 years; 2. Age <60 years and cessation of regular menses for at least 12 consecutive months with no alternative pathological or physiological cause; and serum estradiol and/or FSH level within the laboratory's reference range for postmenopausal females; 3. Documented bilateral oophorectomy. 3. Eastern Cooperative Oncology Group (ECOG) performance status lower or equal to 1. 4. Life expectancy greater or equal to 12 weeks. 5. Histologically proven diagnosed of ABC not amenable to curative treatment. 6. Documented recurrent ER-positive and/or progesterone receptor (PgR)-positive (with =1% positive stained cells (according to NCCN National Comprehensive Cancer Network and ASCO American Society of Clinical Oncology guidelines) and HER2-negative (0-1+ by immunohistochemistry (IHC) or 2+ and negative by in situ hybridization (ISH) test) breast cancer in the advanced setting. 7. Radiological or clinical evidence of disease progression on first- line combination of palbociclib plus endocrine therapy (aromatase inhibitor (AI) or fulvestrant). Patients previously treated with the combination of palbociclib and tamoxifen will be excluded. 8. Patients have achieved clinical benefit criteria to a first-line palbociclib-based endocrine regimen (defined as at least stable disease = 24 weeks or partial or complete response confirmed or unconfirmed). 9. Patients must have been treated with a stable minimum dose of 75 mg palbociclib during the last 2 cycles of the prior palbociclib-based regimen. 10. Last dose of palbociclib administered not later than 8 weeks and not earlier than 7 days from study entry, with the exception of patients relapsing on a palbociclib-based regimen in the adjuvant setting. 11. Patients should not have been treated in the advanced setting with at least one of these endocrine therapy options: either fulvestrant or AI. 12. Patients must have measurable disease or evaluable disease according to RECIST criteria v.1.1. Patients with only bone lesions are eligible. 13. Willingness and ability to provide tumor biopsy (if feasible) both at the time of the inclusion and after disease progression in order to perform exploratory studies. If not feasible, patient eligibility should be evaluated by a Sponsor's qualified designee. 14. Patients agree to collection of blood samples (liquid biopsy) at the time of inclusion, after 2 weeks of treatment, and upon progression or study termination. 15. Adequate organ function: (Hematological, hepatic and renal) 16. Patients who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures. 17. Patients have been informed about the nature of study, and have agreed to participate in the study, and signed the informed consent form prior to participation in any study-related activities. 18. Resolution of all acute toxic effects of prior anti-cancer therapy to grade 1 Exclusion Criteria: 1. HR or HER2 unknown disease. 2. HER2-positive disease based on local laboratory results (performed by IHC / ISH test). 3. Locally ABC candidate for curative treatment. 4. Formal contraindication to endocrine therapy defined as visceral crisis and rapidly or symptomatic progressive visceral disease. 5. Prior therapy with any other CDK4/6 inhibitor different from palbociclib. 6. Known active uncontrolled or symptomatic Central Nervous System (CNS) metastases, carcinomatous meningitis, or leptomeningeal disease as indicated by clinical symptoms, cerebral edema, and/or progressive growth. Patients with a history of CNS metastases or cord compression are eligible if they have been definitively treated and are clinically stable off anticonvulsants and steroids for at least 4 weeks before randomization. 7. Patients are currently receiving food or drugs known to be strong inducers or inhibitors of CYP3A4. 8. Current or prior malignancy which could affect compliance with the protocol or interpretation of results. Patients with curatively- treated non-melanoma skin cancer, non-muscle-invasive bladder cancer, or carcinoma in situ, among others, are generally eligible. 9. No other systemic therapy for metastatic disease including chemotherapy, immunotherapy, targeted therapy (small molecules/ monoclonal antibodies), or endocrine therapy excluding first-line palbociclib-based regimen. 10. Major surgery (defined as requiring general anesthesia) or significant traumatic injury within 2 weeks of start of study drug, or patients who have not recovered from the side effects of any major surgery, or patients who may require major surgery during the study. 11. Radiotherapy or limited-field palliative radiotherapy within 7 days prior to study enrolment, or patients who have not recovered from radiotherapy-related toxicities to baseline or grade = 1 and/or from whom = 25% of the bone marrow has been previously irradiated. 12. Use of concurrent investigational agents or other concomitant anticancer therapies. 13. Active bleeding diathesis, previous history of bleeding diathesis, or chronic anti-coagulation treatment (the use of low molecular weight heparin is allowed as soon as it is used as prophylaxis intention). 14. Serious concomitant systemic disorder (e.g., active infection including HIV, or cardiac disease) incompatible with the study (at the discretion of investigator). 15. Unable to swallow capsules or tablets. 16. History of malabsorption syndrome or other condition that would interfere with enteral absorption. 17. Any of the following within 6 months of randomization: myocardial infarction, severe/unstable angina, ongoing cardiac dysrhythmias of NCI-CTCAE v.5.0 grade =2, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident including transient ischemic attack, or symptomatic pulmonary embolism. 18. Uncontrolled electrolyte disorders of NCI-CTCAE v.5.0 grade = 2. 19. Known hypersensitivity to palbociclib or any of its excipients. |
Country | Name | City | State |
---|---|---|---|
France | Hôpital Jean Minjoz | Besançon | |
France | Polyclinique Bordeaux Nord Aquitaine | Bordeaux | |
France | Centre Georges François Leclerc | Dijon | |
France | CHD Vendee | La Roche-sur-Yon | |
France | Hopital Europeen Georges Pompidou | Paris | |
France | Hôpital Tenon AP-HP | Paris | |
France | Centre Paul Strauss | Strasbourg | |
Germany | University Hospital Dresden-GYN | Dresden | |
Germany | Kliniken Essen Mitte | Essen | |
Germany | Universitätsklinikum Essen Frauenklinik | Essen | |
Germany | AGAPLESION Markus Krankenhaus | Frankfurt | |
Germany | Technical University Munich | Munich | |
Germany | UKM Brustzentrum | Münster | |
Germany | Klinikum Ernst von Bergmann | Potsdam | |
Germany | Klinikum Mutterhaus der Borromäerinnen Trier | Trier | |
Italy | Ospedale Civili Brescia | Brescia | |
Italy | Instituto Europeo di Oncologia | Milano | |
Italy | Oncologia Medica Ospedale di Prato | Prato | |
Italy | Policlinico Universitario Campus Bio-medico | Roma | |
Slovenia | Onkološki Inštitut Ljubljana | Ljubljana | |
Slovenia | Univerzitetni klinicni center Maribor Oddelek za onkologijo | Maribor | |
Spain | Centro Oncológico de Galicia | A Coruña | |
Spain | ICO Badalona | Badalona | Barcelona |
Spain | H. Vall Hebrón | Barcelona | |
Spain | Hospital del Mar | Barcelona | |
Spain | Institut Català d'Oncologia Bellvitge | Barcelona | |
Spain | Hospital de Basurto | Bilbao | |
Spain | Hospital San Pedro de Alcantara | Cáceres | |
Spain | Hospital Provincial de Castellón | Castello | Castelló |
Spain | Institut Català d'Oncologia | Girona | |
Spain | Hospital Arnau de Vilanova | Lleida | |
Spain | Hospital Clinico San Carlos | Madrid | |
Spain | Hospital La Paz | Madrid | |
Spain | Hospital Universitario Sanchinarro | Madrid | |
Spain | Hospital Regional Universitario de Malaga | Málaga | |
Spain | Hospital Universitari Son Espases | Palma De Mallorca | |
Spain | Hospital Sant Joan | Reus | |
Spain | Hospital Universitario Virgen de la Macarena | Sevilla | |
Spain | Hospital Universitario Virgen del Rocío | Sevilla | |
Spain | Consorci Sanitari de Terrassa | Terrassa | Terrasa |
Spain | Hospital Arnau de Vilanova de Valencia | Valencia | |
Spain | Hospital General Universitari de Valencia | Valencia | |
Spain | Hospital Universitari i Politecnic La Fe | Valencia | |
Spain | Instituto Valenciano de Oncología IVO | Valencia | |
Spain | Hospital Álvaro Cunqueiro | Vigo | |
Spain | Hospital Lozano Blesa | Zaragoza | |
Spain | Hospital Miguel Servet | Zaragoza | |
United Kingdom | Darent Valley Hospital by Dartford and Gravesham NHS Trust | Dartford | |
United Kingdom | Beatson West of Scotland Cancer Center | Glasgow | |
United Kingdom | Barts Cancer Institute | London | |
United Kingdom | Kent Oncology Department | Maidstone | |
United Kingdom | Abertawe Bro Morgannwg University Local Health Board, Singleton Hospital | Swansea | |
United Kingdom | Royal Cornwall Hospital NHS Trust | Truro |
Lead Sponsor | Collaborator |
---|---|
MedSIR | Pfizer |
France, Germany, Italy, Slovenia, Spain, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | PFS (Progression-free survival) | From a clinical point of view, the primary endpoint for this study is the PFS (progression-free survival) - defined as the period of time from randomization until objective tumor progression or death - assessed by RECIST criteria v.1.1, of continuation of palbociclib treatment combined with second-line endocrine therapy (letrozole or fulvestrant) versus endocrine therapy in pre- and post- menopausal women with HR-positive/HER2-negative ABC. | Baseline up to 29 months | |
Secondary | Safety AEs | Patient safety and adverse events (AEs) will be evaluated using the NCI-CTCAE v.5.0. Grade 3 and 4 AEs and serious adverse events (SAEs) will be assessed to determine the safety and tolerability of the different treatment arms. | Baseline up to 29 months | |
Secondary | Efficacy (ORR) | To compare the objective response rate (ORR), the duration of response (DoR), the time to response (TTR), the clinical benefit rate (CBR), the time to progression (TTP), and the overall survival (OS) of palbociclib plus second-line endocrine therapy (letrozole or fulvestrant) versus endocrine therapy alone | Baseline up to 29 months | |
Secondary | Efficacy (Quality of Life) | To compare the patient reported global Quality of Life (QOL), functioning and symptoms of palbociclib plus second-line endocrine therapy (letrozole or fulvestrant) versus endocrine therapy alone. | Baseline up to 42 months | |
Secondary | Efficacy of subgroup analysis | To perform subgroup analysis for primary and secondary endpoints in stratified groups of patients. | Baseline up to 42 months | |
Secondary | Compare efficacy | To compare the time to first chemotherapy of palbociclib plus second-line endocrine therapy (letrozole or fulvestrant) versus endocrine therapy alone. | Baseline up to 42 months | |
Secondary | Exploratory objectives (molecular markers) | To explore potential molecular markers of sensitivity and/or resistance for the combination and endocrine therapy alone, according to, but not limited to, the results obtained from the BioPER trial (NCT03184090). | Baseline up to 42 months | |
Secondary | Exploratory objectives (intrinsic molecular subtypes) | To explore correlations between the intrinsic molecular subtypes and efficacy/safety findings in patients with HR-positive/HER2- negative ABC. | Baseline up to 42 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A |